Allied Medipharma Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
- Paid Up Capital ₹ 1.50 M
- Company Age 5 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 6.80 M
- Revenue Growth 90.61%
- Profit Growth 27.60%
- Ebitda -523.97%
- Net Worth 64.61%
- Total Assets 290.76%
About Allied Medipharma
Allied Medipharma Private Limited (AMPL) is a Private Limited Indian Non-Government Company incorporated in India on 07 August 2019 (Five years and six months 18 days old ). Its registered office is in Bardhaman, West Bengal, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 1.50 M.
The company currently has active open charges totaling ₹6.80 M.
Sonanki Dey, Amanisha Dutta, and Tuhin Dey serve as directors at the Company.
Company Details
- Location
Bardhaman, West Bengal, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24304WB2019PTC233331
- Company No.
233331
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Aug 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Who are the key members and board of directors at Allied Medipharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sonanki Dey  | Director | 07-Aug-2019 | Current |
| Amanisha Dutta | Director | 01-May-2021 | Current |
| Tuhin Dey | Director | 07-Aug-2019 | Current |
Financial Performance of Allied Medipharma.
Allied Medipharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 90.61% increase. The company also saw a substantial improvement in profitability, with a 27.6% increase in profit. The company's net worth Soared by an impressive increase of 64.61%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Allied Medipharma?
In 2021, Allied Medipharma had a promoter holding of 40.00% and a public holding of 60.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹6.80 M
₹0
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 0.60 Cr
- Others : 0.08 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 13 Feb 2024 | Hdfc Bank Limited | ₹6.00 M | Open |
| 15 Dec 2022 | Others | ₹0.80 M | Open |
How Many Employees Work at Allied Medipharma?
Allied Medipharma has a workforce of 50 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Allied Medipharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Allied Medipharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.